|Articles|January 1, 2012
Rising Proportion of New and Modified Indication Approvals
Author(s)Tufts Center for Drug Development
Tufts Center for Drug Development
Advertisement
In an effort to extend product life cycles and generate larger and longer revenue streams per product, pharmaceutical and biotechnology companies have stepped up their efforts to seek approval for new or modified indications of already approved drugs.
A recent study conducted by the Tufts Center for the Study of Drug Development finds that the number of new or modified indication approvals following the original new drug approval (NDA) increased 17% between the periods 1998 to 2003 and 2004 to 2009. Original NDAs as a proportion of total drug approvals continues to decline gradually. The number of new drug approvals for pediatric indications following original NDAs rose sharply, increasing 107% between 1998 and 2009. The number of NDA new indications increased 15%, and the number of supplemental NDA new indications declined 5% during this period. Anti-infective and CNS drugs each accounted for one-fifth of all new or modified indication approvals between 1998 and 2009. Cardiovascular and oncology drugs accounted for 15% and 13% of all new or modified indications respectively. Moving forward, with finite resources, sponsors must strike the right balance in maximizing portfolio value by allocating R&D resources between novel, original NDAs, and new or modified indication approvals.
—Tufts Center for the Study of Drug Development, http://csdd.tufts.edu .
Articles in this issue
over 13 years ago
Applied Clinical Trials Digital Edition - January 2012over 13 years ago
Risk & Resources to Shape Trial Operationsover 13 years ago
CV Safety for Developersover 13 years ago
Rising Proportion of New and Modified Indication Approvalsover 13 years ago
Risk-based Approach to Monitoringover 13 years ago
Limited Resource Trialsover 13 years ago
Imaging Pharmacovigilance Needs Overhaulover 13 years ago
Refined Safety Assessmentsover 13 years ago
Biotech's Long Road to Savvyover 13 years ago
Imperatives to Share Trial Results with Volunteersover 13 years ago
Snapshot Shows Targeted Site Monitoring Trendover 13 years ago
A Race to the Finish for CTs in Europe?over 13 years ago
Emerging Opportunity in GuatemalaNewsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
- Using AI Trial-Matching Tools to Accelerate Patient Access
September 8th 2025
- How AI Can Help Physicians Identify Eligible Trials Faster
September 5th 2025
Advertisement
Advertisement